Top Markets
Coin of the day
Solvonis Therapeutics plc Solvonis Therapeutics plc

Solvonis Therapeutics plc

SVNS
Peringkat dalam Saham #40469
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January... Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Harga Saham
$0.00204105
Kapitalisasi Pasar
$138.92K
Perubahan (1 hari)
5.63%
Perubahan (1 tahun)
-60.44%
Negara
GB
Perdagangan Solvonis Therapeutics plc (SVNS)

Kategori

Margin Operasi untuk Solvonis Therapeutics plc (SVNS)
Margin Operasi per 2026 TTM: 0.00%
Menurut laporan keuangan dan harga saham terbaru dari Solvonis Therapeutics plc, margin operasi saat ini (TTM) adalah 0.00%. Pada akhir 2026, margin operasi perusahaan adalah 0.00%.
Riwayat margin operasi untuk Solvonis Therapeutics plc dari 2026 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Margin Operasi untuk perusahaan sejenis atau pesaing
Perusahaan Margin Operasi Perbedaan Margin Operasi Negara
0.00% -
US
11.56% -
DE
0.00% -
FR
0.00% -
DE
20.87% -
US
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.